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10 96,177 d4T/3TC 327 116 <400 >30,000 580 Yes
11 81,000 d4T/3TC 528 87 <50 30,000 <400 -
Table 1. Study patients
Mean CD4+ nadir: 263 cells/mm3
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SUMMARY – CONCLUSIONS
• The efficacy of NVP-based regimens was not reduced following reintroduction of ART after ART interruption
in most patients
• The failure in patient 10 could be attributed to reported noncompliance (no genotype available).
Numerous studies have shown that noncompliance greatly reduces the efficacy of NVP regimens
through the selection of resistance-conferring mutations.16 Patient 17 had an impeccable history of com-
pliance and reported good compliance following STI. Therefore, STI cannot be ruled out as the main
contributing factor to the selection of the Y181C mutation in this patient
• Both patients failing to resuppress had a high BLVL (10: 96,177;17: 351,288). However, most patients
with BLVL >100,000 copies/mL (75.0%, N = 4) did resuppress after ART-i
• The mean BLVL was significantly higher than the mean VL measured during the ART-i 
(∆VL = -0.808 log10, P = 0.009). Caution must be exercised when drawing conclusions from this result.
The interruption period was not the same for all patients, and a viral load set point may not have been
reached in some 
• The mean duration of ART was approximately three times the duration of ART-i. Due to the study
design, we could not accurately measure the duration of BLQ while on ART. The duration of BLQ would
be more appropriate to measure in future prospective trials, as it takes certain patients longer than 
others to reach BLQ and to have sufficient increase in CD4+ to impact a reduction in rebound VL1
• It is important to note that patients in this study stopped ALL medications simultaneously. Recent 
discussion has suggested the strategy of sequential interruption, stopping NsRTIs 48 hours after 
stopping NNRTIs. This may provide the necessary additional inhibition of resistant viral outgrowth
during the slow decline of NNRTI concentration 
• ART interruptions have been a common part of clinical practice since the development of PIs, with
interruption rates ranging from 36.2% to 45.9%.1,17 As the need for long-term ART becomes more 
evident, we should study and examine the effects of STI. We could then utilize this inevitable event as
a benefit to the patient, be it through virologic control or temporary relief from AEs
• In summary, following ART-i, reinitiating NVP and two NsRTIs resulted in the suppression of viral
replication to BLQ in most adherent patients. Utilizing sequential interruption of NNRTI-based 
regimens should allow for the design of easier STI protocols. Further examination of this and all
aspects of STI is warranted
Acknowledgments: Thanks to Alison Stapler, Judy Lash, Juanita Goodwin, and Terry Klar.
BACKGROUND
Because of the need for long-term adherence to and emerging long-term toxicity of antiretroviral therapy (ART), it has
become apparent that long-term continuous ART may not be possible for most HIV-1 chronically infected patients.
Alternative treatment strategies are being examined, including Structured Treatment Interruptions (STI). Thus far, the
results of numerous small trials have been variable, with some suggesting immunologic control of viral replication off
ART and others showing viral rebound to baseline or above.1-15 Although little has been proven about the safety and the-
orized induction of virologic control, a few studies have shown that STI does not lead to resistance-conferring 
mutations; treatment efficacy is not reduced following STI in patients on protease inhibitor (PI)-based regimens.5,6,13,15 Due
to the long half-life of NNRTIs and concerns about the development of resistance, non-nucleoside reverse transcriptase
inhibitor (NNRTI)-based regimens have not been included in the design of these trials. With data now 
available showing comparable potency and better tolerability, ART courses in STI trials may be easier if NNRTIs were 
utilized. However, there is a lack of data on the efficacy of reinitiating NNRTIs after STI. To answer this question without
compromising our patients’ ART options, we retrospectively examined the efficacy of nevirapine (NVP)-based regimens
following interruption of the same NVP-based regimen in patients with viral load below the level of quantification (BLQ).
METHODS
• A retrospective chart review of all patients (N = 536) seen from 9/96 to 4/00 was conducted at Bornemann
Internal Medicine (BIM), an urban HIV clinic
• The term antiretroviral therapy interruption (ART-i) was used instead of STI due to the retrospective nature of this study.
Most of the interruptions were due to adverse events (AEs) and other factors, and not due to an attempt at induction
of immunologic control of viral replication, or an attempt at reversion of resistant viral populations to wild-type. ART-i
was defined as simultaneous cessation of the entire antiretroviral regimen for greater than seven (7) days.
• Charts were abstracted for the following: baseline study patient demographics, NVP-containing regimen, treatment
duration, VL before and during ART-i, ART-i duration, and VL after reinitiation of the same NVP-based regimen.
• BLQ was defined as less than 400 HIV-1 RNA copies/mL plasma (<50, if available)
ABSTRACT
Background: Previous studies have  suggested that STI with a protease inhibitor (PI) regimen does not result in resistance-
conferring mutations or reduced treatment efficacy upon reinitiation. Prospective trials will likely not  be performed with
NNRTIs due to their low genetic barrier. This study evaluates the effectiveness of reinitiation of NVP and dual NsRTI after
an antiretroviral therapy interruption (ART-i) in patients with viral load (VL) below the level of quantification (BLQ) on the
same regimen. Methods: Retrospective chart review of all patients (N = 536) seen 9/96 to 4/00 yielded 135 patients on
NVP and dual NsRTIs. Charts were abstracted for NVP regimen, treatment duration, VL before/during ART-i, ART-i 
duration, and VL after reinitiation. ART-i was defined as simultaneous cessation of entire regimen for ≥7 days. BLQ was
defined as <400 HIV RNA copies/mL plasma (<50 copies/mL, if available). Results: 17/135 had VL BLQ with documented
ART-i followed by initiation of the same regimen; 2/17 had a 2nd ART-i and 2/17 had a 3rd ART-i yielding 23 total ART-i
for analysis. Mean baseline VL (BLVL) was 108,276 (5.03 log10) copies/mL. Mean initial ART duration was 193 days. Mean 
ART-i duration was 58 days. Upon reinitiation, VL fell BLQ (<400 copies/mL) in 21 of 23 interruptions (91.3%). 
Nonadherence was associated with one failure, while viral isolates resistant to NVP (Y181C) were detected in the other.
Conclusions: After ART-i, reinitiating an NVP regimen resulted in resuppression of VL to BLQ in most adherent patients.
These results suggest that an NNRTI does not require switch to a PI prior to planned interruption; however, the possi-
bility of failing to resuppress does exist. A larger retrospective study is indicated. Direct interruption of an NNRTI 
regimen could lead to design of easier and more efficient STI protocols.
Number of patients 17
Average age 36.3 years
Sex: Male 58.8% (10)
Female 41.1% (7)




Table 2. Individual patient results
Patient BLVL NsRTI ART ART-i VL VL VL  Noncompliant?
duration duration before during after





12 341,000 d4T/3TC -
9 7,219 d4T/3TC -
37 45 <50 12,278 <400
26 32 <400 167 <50
45 79 <50 1,500 <50
13 20,214 ZDV/3TC 244 39 <400 - <50 -
14 367,481 ZDV/3TC 49 7 <50 - <50 -
15 29,000 ddI/3TC 126 7 <50 <50 <50 -
16 349,091 ddI/3TC 364 20 <50 13,000 <50 -
17 351,288 ddI/3TC 314 64 <50 30,440 1,027* -
Mean 108,276 - 193 58 - 16,830 - -
10 96,177 d4T/3TC 327 116 <400 >30,000 580 Yes
11 81,000 d4T/3TC 528 87 <50 30,000 <400 -
7 64,592 d4T/3TC 150 7 <50 - <50 -
8 5,500 d4T/3TC 229 116 <50 6,100 <50 -
6 8,689 d4T/3TC -
1 23,294 ZDV/3TC 214 72 <400 26,701 <50 -
2 47,177 d4T/3TC 161 21 <400 66,699 <50 -
486 162 <50 646 <50
3 7,490 d4T/3TC 229 35 <50 <50 <50 -
150 20 <50 - <50
4 2,487 d4T/3TC 141 17 <400 27,879 <50 -
5 39,000 d4T/3TC 213 96 <50 5,200 <50 -
83 22 <400 - <400
125 45 <400 23,238 <50
151 51 <400 - <400
44 82 <400 3,000 <50
*Viral isolates contained Y181C mutation.
21/23 patients (91.3%) achieved resuppression of viral load following reintroduction of NVP regimen.
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